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Neurobiology of Disease

Bcl-x Pre-mRNA Splicing Regulates Brain Injury after
Neonatal Hypoxia-Ischemia
Qingli Xiao, Andria L. Ford, Jan Xu, Ping Yan, Kuang-Yung Lee, Ernesto Gonzales, Tim West, David M. Holtzman,
and Jin-Moo Lee
Hope Center for Neurological Disorders and Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110

The bcl-x gene appears to play a critical role in regulating apoptosis in the developing and mature CNS and following CNS injury. Two
isoforms of Bcl-x are produced as a result of alternative pre-mRNA splicing: Bcl-xL (the long form) is anti-apoptotic, while Bcl-xS (short
form) is pro-apoptotic. Despite the antagonistic activities of these two isoforms, little is known about how regulation of alternative
splicing of bcl-x may mediate neural cell apoptosis. Here, we report that apoptotic stimuli (staurosporine or C2-ceramide) reciprocally
altered Bcl-x splicing in neural cells, decreasing Bcl-xL while increasing Bcl-xS. Specific knockdown of Bcl-xS attenuated apoptosis. To
further define regulatory elements that influenced Bcl-x splicing, a Bcl-x minigene was constructed. Deletional analysis revealed several
consensus sequences within intron 2 that altered splicing. We found that the splicing factor, CUG-binding-protein-1 (CUGBP1), bound to
a consensus sequence close to the Bcl-xL 5⬘ splice site, altering the Bcl-xL /Bcl-xS ratio and influencing cell death. In vivo, neonatal
hypoxia–ischemia reciprocally altered Bcl-x pre-mRNA splicing, similar to the in vitro studies. Manipulation of the splice isoforms using
viral gene transfer of Bcl-xS shRNA into the hippocampus of rats before neonatal hypoxia–ischemia decreased vulnerability to injury.
Moreover, alterations in nuclear CUGBP1 preceded Bcl-x splicing changes. These results suggest that alternative pre-mRNA splicing may
be an important regulatory mechanism for cell death after acute neurological injury and may potentially provide novel targets for
intervention.

Introduction
Hypoxic–ischemic insults to the perinatal brain frequently lead
to severe brain injury with resultant intellectual impairment, motor disability, and seizures at later ages. Animal studies have
shown that the mechanisms leading to injury in the developing
brain are distinct from those involved in adult brain injury (Back
et al., 2002; McQuillen et al., 2003). Though not an exclusive
injury mechanism, apoptosis appears to play a prominent role in
neonatal hypoxia–ischemia (H–I), as this cascade is easily engaged after brain insults during this developmental stage (Pulera
et al., 1998; Nakajima et al., 2000). A proximal and important
regulator of apoptosis is the mitochondrial protein Bcl-xL, which
is highly expressed during embryonic development in the CNS.
Deletion of bcl-x, the gene that encodes Bcl-xL, in mice results in
massive neuronal death in the brain, spinal cord, and dorsal root
ganglia during late embryonic development (Motoyama et al.,
1995), indicating that bcl-x is important for neuronal survival.
Moreover, Bcl-xL overexpression attenuates brain injury caused
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by a variety of CNS insults, including H–I in neonatal rodents
(Parsadanian et al., 1998; Wiessner et al., 1999; Cao et al., 2002;
Yin et al., 2006).
The bcl-x gene generates two protein products with opposing
actions as a result of alternative pre-mRNA splicing: Bcl-xL (the
longer form) is anti-apoptotic, while Bcl-xS (the short form) is
pro-apoptotic. Recent studies in a variety of cancer cell lines have
shown that Bcl-xL appears to be reciprocally regulated with Bcl-xS
following apoptotic stimuli, suggesting that alternative premRNA splicing of Bcl-x pre-mRNA may be a critical regulator of
programmed cell death. Treatment of A549 adenocarcinoma
cells with the apoptosis-inducing agent ceramide resulted in increased Bcl-xS and a concomitant decrease in Bcl-xL mRNA
(Chalfant et al., 2002). Two cis-elements (CRCE1 and CRCE2)
within exon 2 were shown to be necessary for ceramide-induced
splicing effects (Massiello et al., 2004), and SAP155 was identified
as the splicing factor that bound to CRCE1, inducing A549 cell
death (Massiello et al., 2006). Other groups have demonstrated
that altering pre-mRNA splicing of Bcl-x, using antisense oligonucleotides targeted at the Bcl-xL splice site, increased susceptibility to cell death (Taylor et al., 1999; Mercatante et al., 2001;
Villemaire et al., 2003). Indeed, it has been proposed that a critical ratio of Bcl-xL to Bcl-xS is required to maintain cell survival
(Minn et al., 1996).
While several studies have investigated Bcl-x pre-mRNA
splicing in vitro using cell lines, few have explored its role in vivo
in apoptosis or other pathological models of injury. Moreover,
there are no studies that have demonstrated a requirement for
endogenous Bcl-xS expression in cell death. In this study, we
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sought to determine whether the regulation
of Bcl-x alternative pre-mRNA splicing was
an important mechanism of neural cell
death following neonatal H–I.

Materials and Methods
Cell culture and death assessment. Rat oligodendrocyte progenitor (OP) cells were cultured as
described previously (Zhang et al., 1999), with
slight modifications. The cells were grown
in progenitor medium (69% DMEM/F-12/
HEPES containing N1 supplement, 10 g/ml insulin, 20 nM progesterone, 100 units penicillinstreptomycin, 30% conditioned medium from
B104 cells, and 1% FBS) and plated on 100 mm
culture dishes precoated with poly-L-lysine. Disaggregated oligosphere cells displayed bipolar or
tripolar morphology. OP cells were maintained
in growth medium and treated with various
concentrations (0 –100 M) of C2-ceramide
(Biomol) for varying times. Cell viability was assessed by lactate dehydrogenase (LDH) and the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay as described previously (Xu et al., 2000). For DNA laddering,
OP cells were homogenized and incubated in
a lysis buffer containing RNase A and proteinase K overnight at 37°C. After extraction,
DNA pellets were dissolved in Tris-EDTA
buffer and electrophoresed and visualized by
UV light. Caspase activity was measured using a colorimetric assay kit, CaspACE assay
system (Promega).
Pure neuronal cultures were prepared from
the cortices of embryonic day 15 (E15) mice.
Cortices were collected, digested with 0.25%
trypsin, triturated, then plated in Neurobasal
medium (Invitrogen) supplemented with B27
and 25 M glutamate. Cultures were kept at
37°C in a humidified incubator with 5% CO2.
Oxygen– glucose deprivation was performed
as described previously (Xu et al., 2000).
Briefly, cortical neurons were transferred into a
temperature-controlled (37 ⫾ 1°C) anaerobic
chamber containing a gas mixture composed
of 5% CO2, 10% H2, 85% N2, and 0.1% O2. The
cultures were washed three times with deoxygenated glucose-free HBSS and then kept in the
same medium in the hypoxia chamber for 90 Figure 1. Changes in Bcl-x alternative splicing during apoptosis. A, Oligodendrocyte precursor (OP) cells were treated with
min followed by reoxygenation in a normoxic varying concentrations of C2-ceramide as indicated for 24 h. Total RNA was extracted and analyzed by RT-PCR for alternative
incubator under 5% CO2/95% air for 3–24 h. splicing of Bcl-x (noted below the gels are the Bcl-xL/Bcl-xS ratios). The bottom graphs show cell death by LDH release. B, OP cells
Cells exposed to HBSS in a normoxic incubator were treated with 50 M C2-ceramide for varying times as indicated. Total RNA was extracted and analyzed by RT-PCR for
alternative splicing of Bcl-x, and Bcl-xL/Bcl-xS ratios were quantified. C–F, OP cells were treated with 50 M C2-ceramide for
served as a control.
Construction of minigene and splicing factor ex- varying times and immunoblotted for Bcl-xL and Bcl-xS (C), assayed for caspase-3 activity (D), DNA fragmentation (E), and cell
pression vectors. The minigenes were constructed survival (MTT) and death (LDH) (F ). Data were expressed as mean ⫾ SE of three independent experiments. G, Cortical neurons
by amplifying regions of the bcl-x gene from rat were treated with 40 M C2-ceramide or 100 nM staurosporine for 24 h or oxygen glucose deprivation for 90 min, followed by
genomic DNA by PCR using primers containing reoxygenation for varying times (3–24 h as indicated). Shown are RT-PCR products showing reciprocal changes in Bcl-x splice
unique NheI, EcoRI, BglII, and XhoI restriction isoforms.
sites to allow replacement of segments of the
minigene as cassettes. Briefly, the 2.6 kb fragment
inserted between the NheI and XhoI sites of pcDNA3.1 vector (Invitroof bcl-x containing 3⬘-end of exon 1, intron 1, exon 2 and 5⬘-end of intron 2
gen), which contains the CMV promoter. Intron 2 deleted constructs
was generated using a forward primer: Nf, 5⬘-ATTCCGCTAGCCTGCCTA
were generated by PCR using the common forward primer Nf and folCCAGGTC-3⬘, and a reverse primer: Er, 5⬘-CTGGAATTCTGCCCCTCC
lowing reverse primers: D1 (5⬘-GGAGAATTCGCTACTCTCCTAGGT
TATAATCAGC-3⬘ (restriction sites are underlined). Another 0.5 kb
T-3⬘), D2 (5⬘-AGCCAGAATTCAAAATACAGGTTCC-3⬘), D3 (5⬘-CC
fragment of bcl-x containing 3⬘-end of intron 2 and 5⬘-end of exon 3 was
TGAATTCTCGATATCTTCAACAAC-3⬘), D4 (5⬘-AGGGAATTCCAC
generated by forward primer: Ef, 5⬘-AGAAGAATTCTCTGTCTGAA
AGAGGAGAGACACAC-3⬘), D5 (5⬘-GGCGGATTCACAAGGGGCGT
AGTCC-3⬘, and reverse primer: Xr, 5⬘-AGGCTCGAGCGGTTGAAACG
GGTTCT-3⬘). For U/G motif truncated construct, the upstream
fragment was produced by Nf and a reverse primer Bgr, 5⬘-CTGAGATC
CTCCTGGC-3⬘. Both of the aforementioned fragments were ligated and
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TGGGGCGTGGTTC-3⬘. The downstream fragment was generated by
Xr and a forward primer Bgf, 5⬘-CTTAGATCTCTCTTCCTCTGT-3⬘.
The above two PCR fragments were ligated and cloned into pcDNA3.1
digested with NheI and XhoI. Site-directed mutagenesis of bcl-x minigene was performed using the GeneTailor mutagenesis kit (Invitrogen)
and the following primer: 5⬘-CCTTGACTGTCCGCCCCTTGACTGTC
TCTCCTCT-3⬘. cDNA sequence of the CUG-binding protein CUGBP1
(NM_006560) was PCR amplified using a forward primer: 5⬘-CTCAGC
TAGCAGAAAATGAACGGCAC-3⬘, and a reverse primer: 5⬘-CAGAAT
TCAGCACGCTCAGTAGGGCT-3⬘ and subcloned into pcDNA3.1
vector with BamHI and EcoRI restriction sites. All constructs were confirmed by sequence analysis.
Cell transfection and RT-PCR. Cells were transfected with the minigene
with or without a CUGBP1 expression vector using Lipofectamine 2000
(Invitrogen). After 36 – 48 h, transfected cells were washed with ice-cold PBS
and harvested. Cells or frozen brain tissues were homogenized and total
RNA was isolated using TRI reagent (Molecular Research Center) according
to the manufacturer’s protocol. Two micrograms of total RNA was reversetranscribed with 200 units of reverse transcriptase (Promega) and 0.5 g of
oligo(dT)15 in a total reaction volume of 20 l under the conditions provided by the manufacturer’s protocol. To assess endogenous Bcl-x expression, a PCR with 5⬘-TTGGACAATGGACTGGTTGA-3⬘ (forward) and 5⬘CGGCTCTCGGGTGCTGTATTGTTC-3⬘ (reverse) was performed. To
measure the level of minigene-derived mRNA isoforms, the Bcl-x
exon 2 forward primer (5⬘-AGTTTGGATGCGCGGGAGGTAATC-3⬘)
and pcDNA3.1 reverse primer BGH Rev (5⬘-TAGAAGGCACAGTCGAGG3⬘) were used. PCR products were electrophoretically separated, and the
Bcl-xL/Bcl-xS mRNA ratio was calculated.
RNA interference. For knockdown of Bcl-xS, the paired Bcl-xS shRNA
sequence in pSIREN-RetroQ-ZsGreen vector (Clontech) was as follows:
5⬘-gatccGGAGCTTTGAACAGGACACTTTCTTCCTGTCAAAAGTGT
CCTGTTCAAAGCTCCTTTTTTACGCGTg-3⬘ and 5⬘-aattcACGCGTA
AAAAAGGAGCTTTGAACAGGACACTTTTGACAGGAAGAAAGTGTC
CTGTTCAAAGCTCCg-3⬘.
A complementary pair of scrambled oligonucleotides was used as control.
Two siRNA sequences (synthesized by Integrated DNA Technologies) were
used to target rat CUGBP1: si-1 sense sequence (5⬘-CCAGAUCUUGAUGC
UAUCAdTdT-3⬘) and antisense sequence (5⬘-UGAUAGCAUCAAGAUC
UGGdTdT-3⬘); si-2sensesequence(5⬘-UGUAACAAAACAGCACCCUdTd
T-3⬘) and antisense sequence (5⬘-AGGGUGCUGUUUUGUUACAdTdT3⬘). Duplex siRNA was transfected into OP cells at 200 nM using
Lipofectamine 2000 (Invitrogen). RNA or protein was extracted 48 h
after transfection.
Cell fractionation and immunoblotting. Nuclear and cytosolic protein
extracts were prepared as described (Xu et al., 1997; Yin et al., 2002).
Briefly, tissue or cells were harvested and resuspended in 5 volumes of
buffer A (20 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA, 1 mM
EGTA, 250 mM sucrose, 0.1 mM PMSF, 1 mM DTT, and 1⫻ protease
inhibitor cocktail, pH 7.9). After 10 min on ice, cells were homogenized
and centrifuged at 750 ⫻ g for 15 min at 4°C; the supernatant (cytosolic
extracts) was collected and subjected to centrifugation at 15,000 ⫻ g for
30 min to remove cellular debris. The nuclear pellet was washed three
times with the same lysis buffer, resuspended in 45 l of buffer B (20 mM
HEPES, 1.5 mM MgCl2, 20 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM
PMSF, 1⫻ protease, and phosphatase inhibitor cocktail, pH 7.9), and 15
l of buffer C (20 mM HEPES, 1.2 M KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2
mM PMSF, 1⫻ protease, and phosphatase inhibitor cocktail, pH 7.9) was
added. Samples were placed on ice for 30 min, centrifuged at 15,000 ⫻ g;
supernatants (nuclear protein) were stored at ⫺80°C. Five micrograms
of nuclear proteins and 20 – 60 g of cytosolic or total proteins were
subjected to SDS-PAGE and transferred to PVDF membranes for detecting proteins using the following antibodies: Bcl-x (GenScript), CUGBP1
(Novus Biologicals), caspase-3 (Cell Signaling Technology), and actin
(Sigma).
Electrophoretic mobility shift assay and UV cross-linking analysis. An RNA
oligo containing U/G motif, 5⬘-CUUGUGUGUCCGCCCCUUGUGUG3⬘, was labeled with [␥- 32P]ATP (PerkinElmer) by T4 polynucleotide kinase
(Promega). RNA-protein binding was carried out at room temperature in 20
l of buffer (10 mM HEPES, pH 7.9, 5 mM MgCl2, 40 mM KCl, 1 mM DTT, 5
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Figure 2. Bcl-xS knockdown attenuates apoptosis. A, Diagram shows Bcl-x pre-mRNA with
mRNA isoforms and shRNA specifically targeted at Bcl-xS. OP cells were infected with a retroviral
vector expressing Bcl-xS shRNA or scramble shRNA for 48 h and then treated with C2-ceramide
(50 M) for 16 h as described in Materials and Methods. ss, splice site. B, RT-PCR was performed
to analyze alternatively spliced Bcl-x isoforms (top), and total proteins were extracted and
analyzed by Western blot for Bcl-xL and Bcl-xS (bottom). C, Cell death was assessed by LDH assay
and expressed as mean ⫾ SE of three independent experiments. **p ⬍ 0.01 compared to
scramble shRNA-treated OP cells.

g of nuclear proteins) for 30 min. Heparin was added to a final concentration of 5 g/l. For competition experiments, unlabeled cold RNA oligo at
50-fold molar excess was added 10 min before the addition of the radiolabeled probe. To identify specific proteins in the electrophoretic mobility shift
assay (EMSA) complex, nuclear extracts were incubated with 2 g of antibody for 15 min before addition of labeled probe. After incubation with the
labeled probe for an additional 30 min, samples were subjected to native 6%
PAGE. For UV cross-linking, the RNA–protein binding mixture was UV
irradiated using a Spectrolinker XL-1000 UV Crosslinker (Fisher Scientific)
for 30 min and then resolved using 10% SDS-PAGE.
Animal models. Animal care and surgical procedures were approved by
the Animal Studies Committee of Washington University School of
Medicine (St. Louis, MO) in accordance with guidelines of the US National Institutes of Health. Pregnant Sprague Dawley dams were obtained
from Charles River at embryonic day 15. Rat pups of both sexes were
subjected to unilateral carotid ligation on postnatal day 7 (P7), followed
by hypoxia as described previously (Han et al., 2002). Briefly, under
halothane anesthesia the left carotid artery was exposed through an incision in the neck and cauterized. The incision was closed with skin glue
and the pups were allowed to recover from anesthesia in a 37°C chamber.
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The pups were returned to the dam for 2 h for
refeeding and recovery after which they were
placed in chambers kept at 37°C through which
humidified 8% oxygen (balance nitrogen)
flowed. After 2.5 h of hypoxia, the pups were
returned to the dam. At various time points (3,
6, 12, and 24 h) after the end of the hypoxia,
animals were killed and perfused with PBS. The
hippocampus and cortex were dissected on ice
and immediately frozen on dry ice.
Lentiviral vector production and hippocampal
injection. The above mentioned Bcl-xS shRNA
or control shRNA was inserted into pRRLsinU6cass-PGK-EGFPppt plasmid (provided by
Mingjie Li, Hope Center for Neurological
Disorders viral core, Washington University
School of Medicine) with AarI sites. shRNA and
EGFP were driven by human U6 and PGK promoter, respectively. Lentiviral vectors (LVs) were
generated by transfection of 293T cells by using
the four-plasmid system (LV plasmid constructs:
pMDLgpRRE, pCMV-G, and pRSV-rev). Culture supernatants were harvested 48 h after
transfection, passed through a 0.45 m filter,
concentrated by ultracentrifugation through a
20% sucrose cushion, and stored at ⫺80°C. Vector titers were determined by transduction of
HT1080 cells and assayed for EGFP expression
using flow cytometry. Pups at P0 were rested on a
bed of ice for anesthetization before being placed
in a modified stereotaxic holder. Two microliters
of lentiviral vectors (1 ⫻ 10 6 infectious particles)
were injected into left hippocampus using the following coordinates: anteroposterior, 1.6 mm; lateral, ⫺1.4 mm; and ventral, ⫺2.4 mm. H–I was
performed at P7.
Histology. One week after H–I, animals were
perfused with PBS followed by 4% paraformaldehyde. The brains were removed, postfixed
overnight, cryoprotected in PBS containing
30% sucrose at 4°C until submerged, and then
embedded and frozen in OCT compound.
Twenty-five micrometer coronal sections were
cut on a freezing–sliding microtome and
mounted on slides. Sections were stained with
Figure 3. UG rich elements modulate alternative splicing of Bcl-x. A, Shown is the structure of the Bcl-x minigene construct with
cresyl violet as described previously (Holtzman et
positions of the primers used to amplify minigene-specific mRNA products. The figure also depicts the PCR fragments obtained
al., 1996). Eight corresponding sections for each
from Bcl-x minigene-transfected HeLa and C6 glioma cells. B, Wild-type (W) and truncated minigenes (D1–D5) shown on the left
animal were scanned using a NanoZoomer highresult
in dramatically different Bcl-xL/Bcl-xS ratios (right). The numbers above each deletion construct indicate the distance
resolution whole-slide scanner (Hamamatsu),
downstream
of the Bcl-xL 5⬘ splice site (ss). C, The wild-type (W) and UG motif-deleted minigenes (22 bp deletion, dUG) alters the
and the volume of hippocampus and cortex were
calculated. The percent volume loss in the le- ratio of Bcl-xL/Bcl-xS in HeLa and C6 cells, favoring Bcl-xS expression. D, Single (M1) or double (M2) mutations in the UG motifs
sioned versus the unlesioned hemisphere was de- resulted in a decrease of Bcl-xL/Bcl-xS ratios. Data were expressed as mean ⫾ SE from three independent experiments.
termined. Brain sections that strongly expressed
EGFP in the hippocampus were selected for analysis.
Results
Immunostaining. Fixed cells or brain sections were washed with PBS
Bcl-x pre-mRNA splicing is a critical regulatory process in
and permeabilized with 0.3% Triton X-100 in PBS for 20 min. Cells or
neural cell apoptosis
sections were incubated with anti-monoclonal CUGBP1 antibody overWe have previously demonstrated that ceramide, a lipid second
night at 4°C and then with goat anti-mouse secondary antibody (Alexa
messenger implicated in cell death pathways, induces apoptosis
Fluor 488, Invitrogen) for 1 h. For double labeling, terminal deoxynuin OP cells (Lee et al., 2004), which are particularly vulnerable to
cleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay
(Millipore Bioscience Research Reagents) was performed to evaluate cell
hypoxic–ischemic brain injury in the neonatal period (Back et al.,
death followed by immunofluorescence staining with CUGBP1 antibody
2002). To determine whether alternative splicing of Bcl-x preand Cy3-conjugated goat anti-mouse secondary antibody. Slides were
mRNA is an important regulatory process in OP cell death, cells
mounted in Vectashield with DAPI (Vector Laboratories) and examined
treated with C2-ceramide (C2) for 24 h, were assessed for Bcl-xL
with a fluorescent microscope (Zeiss).
and Bcl-xS mRNAs and cell death. C2 induced a dose-dependent
Statistical analysis. Values were expressed as mean ⫾ SE. Differences
alteration in Bcl-x mRNA isoforms; changes in Bcl-xL/Bcl-xS rabetween two groups were analyzed by Student’s t test, and more than two
tios occurred at lower concentrations of C2 than that which ingroups were analyzed by one-way ANOVA followed by post hoc Tukey’s
duced cell death (LDH release, Fig. 1 A). Similar changes in Bcl-x
test.
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overlapping deletion between D4 and D5
(a 22-bp segment) because of its dramatic
effect on alternative splicing (favoring
Bcl-xS expression) and its close proximity
to the Bcl-xL 5⬘ splice site. Isolated deletion of this 22-bp sequence confirmed the
importance of this sequence in regulating
Bcl-x alternative splicing, demonstrating
dramatic shifts toward Bcl-xS expression
(Fig. 3C). Further analysis of the deleted
sequence revealed two adjacent UG-rich
sequences. Point mutations in the proximal UG motif resulted in a threefold decrease in the Bcl-xL/Bcl-xS ratio, while
double mutations in both motifs resulted
in a similar decrease in the ratio (Fig. 3D),
indicating the importance of UG motifs in
Figure 4. CUGBP1 binds to the UG-rich elements of Bcl-x pre-mRNA. Five micrograms of nuclear extracts were prepared from OP Bcl-x splice site selection. In addition to
cells and subjected to EMSA by reacting with a 32P-labeled UG rich RNA probe. Fiftyfold excess, unlabeled, nonspecific RNA or the UG-rich element, we identified two
specific cold RNA samples were included to show specificity of the RNA–protein complex. A, B, UV cross-linking (as described in other intronic splicing enhancer consenMaterials and Methods) was performed to analyze the molecular weight of trans-acting factor bound to UG probe (A, star (多) sus sequences between bp 296 and 1508
indicates free probe). CUGBP1, but not ETR-3 antibodies eliminated the binding complex (B). C, A mutant probe (UG⬎AC, similar (Fig. 3B). One of the consensus sequences
to that used in Fig. 3D) does not form the complex. D, Abrogation of binding is shown when nuclear extracts were treated with calf (GGGGG) is known to bind heterogeintestinal alkaline phosphatase (CIP).
neous nuclear ribonucleoproteins (hnRNP F/H), while the other (UGCAUG)
protein isoforms were also observed (Fig. 1C). A time course of
binds to the Fox1/2 family. Further investigation is needed to
cells treated with 50 M C2 revealed that Bcl-x splicing changes
explore the role of these factors in the regulation of Bcl-x splicing.
occurred early (within 1 h; Fig. 1 B) compared to caspase-3 actiThe UG-rich motifs in intron 2 constitute a consensus binding
vation (first detected 8 h after treatment; Fig. 1 D), DNA laddersequence for a family of RNA binding proteins known as the
ing (24 h; Fig. 1 E), and cell death (24 h; Fig. 1 F). Similar changes
CELF (CUG-BP and ETR-3-like factor) family, which is known
in splicing were observed in OP cells treated with the general
to regulate alternative pre-mRNA splicing (Barreau et al., 2006;
protein kinase inhibitor staurosporine, and both apoptotic stimMarquis et al., 2006). To identify trans-regulatory factors binding
uli altered Bcl-x mRNA splicing in C6 glioma cells (data not
to this UG-rich motif, RNA EMSAs were performed. OP cell
shown). Furthermore, primary cortical neurons treated with C2nuclear extracts were incubated with radiolabeled oligonucleoceramide, staurosporine, or oxygen– glucose deprivation demtides containing the UG-rich motif, cross-linked by UV exposure,
onstrated similar changes in Bcl-x splicing, decreasing Bcl-xL
and electrophoresed. Two bands migrating at ⬃50 kDa were
while increasing Bcl-xS (Fig. 1G). These data suggest that recipidentified and eliminated when incubated with an excess cold
rocal Bcl-x alternative splice changes occur widely in neural cells
RNA probe indicating binding specificity (Fig. 4 A). The EMSA
induced by a variety of apoptotic stimuli.
was probed with antibodies to two members of the CELF family,
Though overexpression of Bcl-xS results in cell death in many
CUGBP1 (CUG-binding protein 1) and ETR-3 (elav-type riboin vitro paradigms (Lindenboim et al., 2001; Mitra et al., 2001),
nucleoprotein 3), to identify specific proteins in the EMSA comthe converse experiment (i.e., the effect of selective decrease of
plex. Binding activity was eliminated with the CUGBP1 antibody
endogenous Bcl-xS on cell death) has never been performed. We
but not the ETR-3 antibody (Fig. 4 B). A mutated probe with
designed an shRNA to selectively knock down Bcl-xS expression
double point mutations in the UG motifs (similar to that used in
by targeting the Bcl-xS 5⬘ splice site (Fig. 2 A). Knockdown reFig. 3D) lacked RNA binding activity, confirming specificity of
sulted in a ⬎75% decrease in Bcl-xS mRNA and protein without
binding (Fig. 4C). Calf intestinal alkaline phosphatase treatment
altering Bcl-xL levels (Fig. 2 B). This knockdown resulted in the
eliminated the binding activity, suggesting that activity was regattenuation of cell death induced by C2 (Fig. 2C), indicating a
ulated by phosphorylation (Fig. 4 D). These findings suggest that
critical role for Bcl-xS in apoptosis.
CUGBP1 specifically binds to the UG-rich motif near the 5⬘ splice
site of Bcl-xL, and that its binding is regulated by phosphorylaCUGBP1 regulates Bcl-x splicing and subsequent cell death
tion. In agreement, the molecular weight of the factor in the UV
Because Bcl-xL and Bcl-xS are both critical regulators of apoptocross-linking experiments (49 –51 kDa; Fig. 4 A) is identical to the
sis, the modulation of Bcl-x alternative splicing is likely to have
known molecular weights of CUGBP1 (hyper- and hypoprofound effects on cell death. To elucidate cis-regulatory elephosphorylated isoforms) (Timchenko et al., 1996).
ments influencing Bcl-x pre-mRNA alternative splicing, a rat
Next, we examined CUGBP1 subcellular expression using imbcl-x minigene was constructed (Fig. 3A). Transfection of this
munocytochemistry, subcellular fractionation, and Western
minigene into both HeLa and C6 glioma cells (to ensure that
blotting. Under basal conditions, CUGBP1 was found promieffects were not cell-line-specific) resulted in the generation of
nently in the nucleus; however, after C2 treatment nuclear
Bcl-xL and Bcl-xS minigene-specific transcripts (Fig. 3A). A series
CUGBP1 content decreased over time (Fig. 5 A, F ). After 24 h,
of progressively larger deletions within intron 2 were created to
CUGBP1 immunoreactivity could be detected in only a few
identify critical cis-regulatory sequences near the Bcl-xL 5⬘ splice
nuclei (Fig. 5A–C). Double-labeling with CUGBP1 immunosite. The serial deletions resulted in changes in the ratio of
staining and TUNEL showed that virtually all of the
Bcl-xL/Bcl-xS mRNA (Fig. 3B). We decided to pursue the nonTUNEL(⫹) cells had exclusive cytoplasmic CUGBP1 localiza-
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Figure 5. Alterations in subcellular CUGBP1 distribution affect Bcl-x splicing and cell death. OP cells were treated with C2-ceramide (50 M) for varying times as indicated. A,
Immunocytochemistry reveals that nuclear CUGBP1 rapidly decreases after treatment with C2-ceramide (top, CUGBP1 immunostaining, green; bottom, overlay of CUGBP1 immunostaining, green, and DAPI staining, blue). B, Double-labeling with CUGBP1 immunostaining (red) and TUNEL (green) after C2-ceramide treatment demonstrates that virtually all
TUNEL(⫹) cells had cytoplasmic CUGBP1. C, D, Subcellular localization of CUGBP1 (C) and TUNEL(⫹) cells (D) were quantified and expressed as mean ⫾ SE. from three independent
experiments. **p ⬍ 0.01 compared to 0 h control (ANOVA with post hoc Tukey’s test). Nuc, Nucleus; Cyto, cytosol. E, Nuclear extracts from OP cells after ceramide treatment demonstrate
decreased UG-rich RNA binding using EMSA. F, Western blots from subcellular fractions of OP cells after ceramide treatment (top) confirm the decrease in nuclear CUGBP1. Blots were
quantified by densitometry, normalized to actin, and expressed as mean ⫾ SE from three independent experiments (bottom), **p ⬍ 0.01 compared to nuclear or cytosol control (ANOVA
with post hoc Tukey’s test). G, OP cells were transfected with CUGBP1 or vector constructs. H, CUGBP1 was knocked down using RNAi. At 24 h post-transfection, ceramide was added to
the cell culture for an additional 16 h. Overexpression and knockdown of CUGBP1 were verified by Western blot (top), alternatively spliced Bcl-x forms were determined by RT-PCR (middle
panel), and cell death was assessed by LDH assay (bottom). *p ⬍ 0.05 si-CUGBP1 versus si-scramble, **p ⬍ 0.01 CUGBP1 construct versus vehicle construct, or si-CUGBP1⫹ceramide
versus si-scramble⫹ceramide (ANOVA with post hoc Tukey’s test). Scale bars, 20 m.
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H–I were killed at various times after H–I.
Within 3– 6 h after H–I, the Bcl-xL/Bcl-xS
ratio was decreased in the ischemic hippocampus and cortex compared to the
contralateral side (Fig. 6 B–E). Further decreases in the Bcl-xL/Bcl-xS ratio were observed up to 24 h after H–I. Sham operated
rats demonstrated no changes in this ratio
(between hemispheres). In both hippocampus and cortex, caspase-3 activation occurred at later time points (12 and 24 h),
suggesting that the Bcl-x pre-mRNA splicing changes preceded this downstream apoptotic event (Fig. 6F,G).
To test whether knocking down Bcl-xS
results in neuroprotection in neonatal
H–I brain injury, a recombinant lentiviral
vector carrying Bcl-xS shRNA was directly
injected into left anterior hippocampus of
the newborn rat. An EGFP gene driven by
a PGK promoter in the same vector demonstrated robust fluorescence in the hippocampus 1 week after injection (Fig. 7A),
indicating successful LV-mediated gene
transfer. At P7, animals were subjected to
unilateral H–I, and killed 1 week later.
Compared to scrambled shRNA, the Bcl-xS
shRNA decreased Bcl-xS without significantly altering Bcl-xL levels in the
LV-injected hippocampus (Fig. 7B). As
expected, both Bcl-xL and Bcl-xS levels did
not change in the cortex (Fig. 7C), demonstrating the anatomic specificity of
LV-mediated shRNA knockdown. H–I resulted in significant brain tissue loss both in
Figure6. Neonatalhypoxia-ischemiaaltersBcl-xalternativesplicing.P7ratsunderwentunilateralcarotidarteryligationandexposure
the hippocampus and cortex when assessed
tohypoxiafor2.5handwerekilledatvaryingtimes(3,6,12,and24h)afterhypoxia.A,Theinfarctedareaofarepresentativebrainsection
isshownbyTTCstaining24hafterH–I.Arrowsindicatecontralateral(C)orischemic(I)hippocampusandcortexusedforRNAextraction.B, 1 week after H–I (Fig. 7D–F). Bcl-xS shRNA
C, Total RNA was extracted and analyzed by RT-PCR for alternative splicing of Bcl-x. A representative agarose gel of the RT-PCR products reduced tissue loss by 47% in the ischemic
from hippocampus (B) or cortex (C) is shown (C, Contralateral hemisphere; I, ischemic hemisphere). D, E, Mean value ⫾ SE of the Bcl-xL/ hippocampus compared to the scrambled
Bcl-xS ratioisfromhippocampus(D)andcortex(E)fromatleast5animalspergroup.*p⬍0.05,**p⬍0.01ischemicversuscontralateral shRNA group; as expected, cortical loss was
(ANOVAwithposthocTukey’stest).F,G,Westernblotswereperformedtomeasureactivatedcaspase-3fromhippocampal(F)andcortical not significantly different between the two
(G) extracts (blots are representative of two independent replicates).
groups (Fig. 7D–F). Thus, Bcl-xS-specific
knockdown protected brain tissue against
tion, and TUNEL(⫺) cells showed progressively more cytoplasH–I-induced cell death, indicating its important role in neural cell
mic CUGBP1 with time (Fig. 5B–D). Consistent with these
injury independent of Bcl-xL effects.
findings, nuclear CUGBP1 RNA-binding activity decreased rapidly after C2 treatment (Fig. 5E). To further examine its reguHypoxia–ischemia alters CUGBP1 expression concomitant
latory role in Bcl-x splicing following injury, CUGBP1 was
with Bcl-x splicing changes
overexpressed in OP cells. Compared to pcDNA3.1, ectopic exWe next sought to determine whether CUGBP1 expression and
pression of CUGBP1 increased Bcl-xL and decreased Bcl-xS, resubcellular localization were altered after neonatal H–I. RNA
sulting in decreased vulnerability to C2 treatment (Fig. 5G).
EMSA showed a marked decrease of CUGBP1 binding activity in
Furthermore, knockdown of CUGBP1 using siRNA resulted in a
cortical nuclear extracts 3 h after H–I compared to the contralatdecrease in the Bcl-xL/Bcl-xS ratio and an increase in C2-induced
eral hemisphere and sham controls (Fig. 8 A). These results were
cell death (Fig. 5H ). These data indicate that CUGBP1 regulates
confirmed by cell fractionation/Western blot and immunohistoBcl-x pre-mRNA splicing and thereby regulates cell death.
chemistry that demonstrated reduced CUGBP1 expression in nuclei (Fig. 8 B, C,E). The fractionation experiments did not show
Effects of Bcl-x alternative splicing in
changes in cytosolic levels of CUGBP1, although the immunoneonatal hypoxia-ischemia
staining showed slightly higher levels in the cytoplasm after H–I
Unilateral H–I in neonatal rats induces well characterized brain
(Fig. 8 B, D,E).
injury within the ipsilateral cortex and hippocampus (Fig. 6 A)
Discussion
with prominent features of apoptosis (Pulera et al., 1998; NakaGiven the critical role of Bcl-xL in cell viability in the developing
jima et al., 2000). To determine whether H–I resulted in alteraand adult nervous system, it is not surprising that alternative
tions in Bcl-x pre-mRNA splicing, P7 rats subjected to unilateral
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Figure 7. Knockdown of Bcl-xS attenuates brain injury following H–I. Lentiviral vectors carrying Bcl-xS shRNA or scrambled (Scram) shRNA were injected into the left hippocampus of P0 rats. A,
A representative example of gene transfer is shown by detecting EGFP expression 1 week after injection. B, C, Animals were subjected to H–I at P7 and killed at P14. Bcl-xL and Bcl-xS mRNA levels
from the hippocampus (B) and cortex (C) were determined by RT-PCR (mean ⫾ SE from 5 animals). D, E, Representative cresyl-violet-stained brain sections from rats from each group (D, scrambled
shRNA: n ⫽ 17; E, Bcl-xS shRNA: n ⫽ 18) are shown. C, Contralateral hemisphere; I, ischemic hemisphere. F, Bcl-xS shRNA significantly reduced tissue loss in hippocampus where shRNA was targeted
but not cortex (mean ⫾ SE; *p ⬍ 0.01 Bcl-xS shRNA versus scrambled shRNA).

splicing of Bcl-x pre-mRNA is tightly regulated under normal
physiological conditions. In this study, we demonstrate the importance of splicing regulation in pathological CNS injury in vivo.
Bcl-x splicing is altered after neonatal H–I, resulting in increased
expression of Bcl-xS relative to Bcl-xL. These splicing changes
occurred earlier than downstream apoptotic events such as
caspase-3 activation and DNA fragmentation, suggesting an upstream regulatory role. Moreover, specifically knocking down the
Bcl-xS isoform (with concomitant changes in Bcl-x isoform ratios) before H–I in neonatal rats resulted in attenuation of brain
injury. Previous studies have shown that overexpression of Bcl-xL
in similar H–I models also attenuates brain injury (Parsadanian
et al., 1998; Yin et al., 2006). Collectively, these data indicate that
the ratio of Bcl-x isoforms plays a critical role in brain injury and
suggest that the coordinate control of both isoforms via splicing
regulation may have additive or synergistic effects.
The pre-mRNA splicing machinery is extremely complex, involving numerous cis-acting splicing sequences, trans-acting
splicing factors, interactions with transcription regulation, and
mRNA export (Chen and Manley, 2009). To identify cis-elements
and trans-factors, we created a Bcl-x minigene. Successive deletions within intron 2 resulted in the identification of several splicing enhancers and suppressors with profound effects on the ratio
of Bcl-xL/Bcl-xS mRNA (Fig. 3). A UG-rich element located
downstream of the Bcl-xL 5⬘ splicing site was identified as an
important sequence for altering splicing, and CUGBP1 was

found to specifically bind to this sequence. In vitro and in vivo
studies revealed that nuclear CUGBP1 content was significantly
reduced after apoptotic stimulation. Furthermore, overexpression of CUGBP1 in vitro increased the Bcl-xL/Bcl-xS ratio, while
RNAi-mediated knockdown decreased the ratio.
CUGBP1 was first identified as a factor binding to pathologically expanded (CUG)n repeats in dystrophia myotonin protein
kinase (DMPK) mRNA found in patients with myotonic dystrophy (Timchenko et al., 1996; Roberts et al., 1997). In this disorder, pathogenesis is related in part to an increase in expression of
CUGBP1, resulting in disrupted regulation of alternative splicing, mRNA translation, and mRNA stability (Philips et al., 1998;
Ranum and Cooper, 2006). CUGBP1 has been reported to regulate alternative splicing of a variety of genes (Philips et al., 1998;
Gromak et al., 2003; Dansithong et al., 2005; Ho et al., 2005) via
binding to UG or UGU motifs (Faustino and Cooper, 2005; Marquis et al., 2006). It is post-translationally regulated by phosphorylation that alters RNA binding activity, increases nuclear
localization, and enhances splicing activity (Roberts et al., 1997).
Our findings of altered subcellular distribution and RNAbinding activity of CUGBP1 following H–I are consistent with
these known regulatory pathways. CUGBP1 ⫺/⫺ mice have been
generated, but a significant proportion of the animals do not
survive past the first few days of life. These animals display growth
retardation and impaired fertility due to increased apoptosis of
germ cells (Kress et al., 2007). Overexpression of CUGBP1 has
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ing modulates neural cell death. Our results suggest that alternative splicing may
be an important regulatory mechanism
for apoptosis after acute neurological injury, and that splicing regulators may be
potential targets for attenuating CNS
injury.
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